Key result
Intracoronary salbutamol increased left ventricular +dP/dt by 44% in unblocked patients versus 25% in those with beta1-selective blockade (P<0.05), evidencing sympathoexcitatory beta2-receptors.
Why the study?
Does intracoronary salbutamol increase left ventricular contractility and cardiac norepinephrine spillover in humans?
Does intracoronary salbutamol increase left ventricular contractility and cardiac norepinephrine spillover in humans?
Intracoronary salbutamol increases left ventricular contractility and cardiac norepinephrine spillover, providing in vivo evidence for sympathoexcitatory cardiac beta2-receptors in humans.
No immediate clinical implications for beta-agonist use; leaves open therapeutic targeting of cardiac beta2-receptors.
BACKGROUND: On the basis of the presence of beta2-receptors within the sympathetic nervous system, beta2-stimulation may increase cardiac sympathetic outflow. We addressed the hypothesis that sympathoexcitatory beta2-receptors are present in the human left ventricle. METHODS AND RESULTS: The beta2-agonist salbutamol was infused into the left coronary artery in 3 groups of patients: group 1 (n=9, no beta-blocker therapy), group 2 (n=7, beta1-selective blockade with atenolol), and group 3 (n=6, nonselective beta-blockade with nadolol). Left ventricular +dP/dt in response to increasing concentrations of salbutamol was measured in all groups, and cardiac norepinephrine spillover was measured in group 1. There were no systemic hemodynamic changes in any group. Salbutamol resulted in a 44+/-6% increase in +dP/dt in group 1, a 25+/-6% increase in group 2 (P<0.05 versus group 1), and no increase in group 3. Salbutamol also resulted in a 124+/-37% increase in cardiac norepinephrine spillover in group 1 (P<0.05). CONCLUSIONS: Evidence that salbutamol increased norepinephrine release from cardiac sympathetic nerves was provided by the observations that atenolol suppressed the salbutamol inotropic response, demonstrating that this response was mediated in part by beta1-receptors and that salbutamol also resulted in an increase in cardiac norepinephrine spillover. This result provides in vivo evidence, in humans, for the role of sympathoexcitatory cardiac beta2-receptors.
No takes yet. Share an insight, caveat, or question.
Newton et al. (1999) studied this question. Salbutamol vs. Atenolol or nadolol was evaluated on Left ventricular +dP/dt (p=<0.05). Intracoronary salbutamol increased left ventricular +dP/dt by 44% in unblocked patients versus 25% in those with beta1-selective blockade (P<0.05), evidencing sympathoexcitatory beta2-receptors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: